Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA-Reference-Cited by-同舟云学术

Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the “magic bullet” to kill cccDNA

Published:2015-11 Issue: Volume:123 Page:193-203
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Zhang Ejuan,Kosinska Anna,Lu Mengji,Yan Huimin,Roggendorf Michael

Publisher

Elsevier BV

Subject

Virology,Pharmacology

Reference139 articles.

1. HDV2 O-09: REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian patients with chronic HBV/HDV co-infection;Bazinet;J. Viral Hepat.,2015

2. Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation;Bengsch;J. Hepatol.,2014

3. T cell receptor-therapy in HBV-related hepatocellularcarcinoma;Bertoletti;Oncoimmunology,2015

4. Chronic hepatitis B: a wave of new therapies on the horizon;Block;Antiviral Res.,2015

5. T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes;Bohne;Gastroenterology,2008

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term hepatitis B surface antigen kinetics after nucleos(t)ide analog discontinuation in patients with noncirrhotic chronic hepatitis B;Liver Research;2024-07

2. The occurrence of immune-related adverse events is an independent risk factor both for serum HBsAg increase and HBV reactivation in HBsAg-positive cancer patients receiving PD-1 inhibitor combinational therapy;Frontiers in Immunology;2024-03-15

3. Effect of solvation on the molecular structure, vibrational assignment, nature of bonding, and the antiviral drug-like potential of troxerutin against HBV proteins;Journal of the Indian Chemical Society;2023-06

4. Overview of the development of HBV small molecule inhibitors;European Journal of Medicinal Chemistry;2023-03

5. PD-1 Inhibitor-based Therapies Could Lead to A Diversity of Viral Kinetics in Cancer Patients with Concomitant HBV Infection;2023-02-21